Elias Papatheodorou has become chairman of the board of directors, with some executive functions, at HepaRegeniX GmbH of Tübingen, Germany. HepaRegeniX is developing regenerative medicines for liver diseases. Mr Papatheodorou was previously chief executive officer of Genkyotex SA, a company focused on fibrosis and acquired by Calliditas Therapeutics AB in 2021. Before that, he was chief business officer of Covagen AG, a developer of protein therapeutics and acquired by Janssen in 2014, and CEO of Novosom AG, an RNA delivery company, which was acquired by Marina Biotech Inc in 2010.
HepaRegeniX announced the appointment on 30 March 2022.
Copyright 2022 Evernow Publishing Ltd